Loading…
Employees: 357
Size NRC Health (NRC) is a United States Health Care company (Services to the Health Industry) with a market value of $572M, the 2600th largest of 3,117 United States companies the cockpit tracks. Shares closed at $25.86 on 6 Nov 2026.
Performance Over six months the shares gained 37.9%, against +22.5% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 6 in its peer set.
Growth Revenue grew 3.4% over the last twelve months (peer median +9.1%); the operating margin is 11.1% (peer median 10.2%).
Valuation It trades at 26.1× forward earnings against a peer median of 19.3× (2nd most expensive of 6).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.7 points above its cost of capital (6.2% WACC).
Backlog Backlog (remaining performance obligations) was $202M at 30 Sep 2026 — 1.4 years of trailing revenue. Backlog detail →
Short interest Short interest is 3.3% of the free float (15 Oct 2026).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $144M | $137M | $143M | $149M | $152M |
| Revenue growth | — | -4% | -4% | -2% | — |
| Gross profit | $78.8M | $77.4M | $80.1M | $86.7M | $89.2M |
| EBITDA | $24.4M | $30.2M | $41.5M | $46.0M | $51.8M |
| Net income | $6.17M | $11.3M | $24.8M | $31.0M | $31.8M |
| Free cash flow | $18.4M | $15.7M | $19.2M | $22.3M | $26.4M |
| Capital expenditure | $5.32M | $10.7M | $15.4M | $15.8M | $9.84M |
| Total debt | $103M | $79.8M | $63.9M | $39.0M | $23.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NRC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +26.6% | +8.5% | 2nd highest of 6 |
| 6-month return | +37.9% | +22.5% | 2nd highest of 6 |
| Distance from 52-week high | -5.7% | -9.9% | 3rd highest of 6 |
| Revenue growth (TTM) | +3.4% | +9.1% | 2nd lowest of 6 |
| Operating margin | 11.1% | 10.2% | 3rd highest of 6 |
| Forward P/E | 26.1× | 19.3× | 2nd most expensive of 6 |
| Growth the price implies (Req g, 7 yrs) | 11.2% | 6.4% | 3rd most demanding of 6 |
| Growth delivered (Del g) | +0.6% | +9.1% | lowest of 6 |
| Hurdle (Req g minus delivered) | +10.5 pp | -7.4 pp | 2nd most demanding of 6 |
| ROIC minus cost of capital | +7.7 pp | +2.7 pp | 2nd highest of 6 |
| EV / EBITDA | 27.5× | 8.5× | most expensive of 4 |
| Net debt / EBITDA | 4.1× | 2.4× | most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| NRC Health NRC | United States | $572M | +38% | +3% | 11% | 26.1× | 11.2% | +0.6% |
| Tokai 9729.T | Japan | $553M | +3% | +5% | 6% | 12.4× | -13.2% | +6.2% |
| Astrana Health ASTH | United States | $1.71B | -12% | +59% | 3% | 19.3× | 12.8% | +35.9% |
| Attendo ATT.ST | Sweden | $1.92B | +23% | -1% | 10% | 17.7× | 1.7% | +9.1% |
| Pro Medicus PME.AX | Australia | $14.8B | +63% | +23% | 75% | 112.9× | 55.0% | +31.0% |
| Quest Diagnostics DGX | United States | $28.1B | +36% | +9% | 15% | 22.0× | 6.4% | +3.2% |
NRC Health reported $202M of remaining performance obligations at 30 Sep 2026. That is 1.4 years of trailing revenue already under contract.